Celcuity Inc. (NASDAQ:CELC) is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, CELC is expected to report 3Q20 loss of $ 0.23 per share.
For the full year, analysts anticipate loss of $ 0.82 per share bottom line.
Stock Performance
On Friday, shares of Celcuity Inc. has traded high as $ 5.69 and has cracked $ 5.33 on the downward trend, reaching $ 5.33 with volume of 4.60 thousand shares.
According to the previous trading day, closing price of $ 5.33, representing a 40.69 % increase from the 52 week low of $ 4.03 and a 63.47 % decrease over the 52 week high of $ 15.52.
The company has a market capital of $ 54.84 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Celcuity Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.celcuity.com
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The companys CELx diagnostic platform uses a patients living tumor cells to identify the specific abnormal cellular process driving a patients cancer and the targeted therapy that treats it. It is developing CELx HSF test to diagnose two new sub-types of HER2-negative breast cancer.
